Small-Cell Lung Cancer – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of SCLC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.

Clarivate Epidemiology’s SCLC forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with SCLC per year?
  • In developing countries, what impact will economic growth and development have on the number of first-line drug-treatment opportunities for SCLC?
  • How will improvements in survival change the number of people living with SCLC?
  • Of all people diagnosed with SCLC, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SCLC over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. 

In total, Clarivate Epidemiology forecasts over 100 SCLC patient populations, including the following:

  • Diagnosed incident cases of SCLC.
  • Diagnosed incident cases of SCLC by stage.
  • Diagnosed metastatic recurrent incident cases of SCLC.
  • Diagnosed prevalent cases of SCLC.
  • Diagnosed first line SCLC extensive drug-treatable population.
  • Diagnosed SCLC drug-treated population.

Note: coverage may vary by country.

launch Related Market Assessment Reports